Peyronie's Disease Treatment
Collagenase (Xiaflex), Modeling, RestoreX Traction, and Surgical Correction
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (collagenase / Xiaflex for Peyronie's, 2013)
Reference only. Not medical advice.
What can go wrong
Collagenase carries a labeled risk of corporal rupture (penile fracture) and serious penile hematoma; injections must be performed by trained clinicians, and patients are warned against sexual activity for a defined window after each cycle. Common effects include penile bruising, swelling, and pain. Surgical options carry risks of erectile dysfunction (highest with incision/grafting), penile shortening (plication), sensory change, and recurrence. Treatment should follow urological evaluation.
This is something to take to a clinician. The Atlas can tell you what is known about peyronie's disease treatment in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Peyronie's disease is an acquired fibrotic disorder in which a collagen plaque forms in the tunica albuginea, producing penile curvature, pain, indentation, shortening, and sometimes erectile dysfunction. It progresses through an active (inflammatory, often painful) phase and a stable phase. Per the AUA Peyronie's Disease Guideline, treatment is matched to phase and severity: intralesional collagenase Clostridium histolyticum (Xiaflex) with penile modeling for stable curvature of roughly 30 to 90 degrees with intact erections, and surgical correction (plication, plaque incision/grafting, or penile prosthesis) for severe, calcified, or refractory disease.
An acquired fibrotic plaque of the tunica albuginea, the one penile-curvature condition with an FDA-approved drug.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Intralesional collagenase (Xiaflex) + modeling
- AUA: moderate recommendation (Grade B) for reduction of curvature in stable disease with dorsal/lateral curve ~30-90 degrees and functional erections. Delivered as injection cycles with clinician and patient modeling.
- Penile traction therapy (RestoreX and others)
- Mechanical traction to reduce curvature and counter length loss; the 2015 AUA guideline judged the evidence insufficient to recommend traction and called for further study, though it is recognized by ISSM and used by many clinicians, often combined with collagenase or perioperatively. Requires sustained daily wear.
- Surgical plication / Nesbit
- Shortens the convex (longer) side to straighten; durable and reliable for curvature but can reduce length. Suited to good erectile function and less severe curves.
- Plaque incision or excision and grafting
- For severe curvature, hourglass deformity, or calcified plaque; straightens by lengthening the concave side, with higher risk of postoperative erectile dysfunction.
- Inflatable penile prosthesis
- Definitive treatment when Peyronie's coexists with refractory erectile dysfunction; straightening maneuvers performed at implantation.
How it works
Collagenase Clostridium histolyticum is a mixture of two clostridial collagenases that enzymatically cleave the type I and type III collagen comprising the plaque, reducing its mechanical tethering effect. It is injected directly into the plaque over a treatment cycle; mechanical 'modeling' (clinician and patient stretching/bending the penis against the curvature) is used between and after injections to help remodel the softened plaque. It treats curvature, not pain and not erectile dysfunction.
The lesion is a fibrous plaque within the tunica albuginea, the bilayered collagen-and-elastin sheath enclosing the corpora cavernosa. The plaque is inelastic relative to surrounding tunica, so during erection the affected side fails to lengthen normally, bending the erect penis toward the plaque. Plaques may calcify over time, which predicts poorer response to nonsurgical therapy.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Intralesional injection and surgical correction of Peyronie's disease carry documented risks including corporal rupture, hematoma, erectile dysfunction, penile shortening, and sensory change. Self-administration is not appropriate; treatment must be performed under specialist urological care.
What people get wrong
Often saidPeyronie's plaques resolve on their own if you wait
ActuallySpontaneous resolution is uncommon; most plaques stabilize rather than disappear, and curvature/shortening often persist. Early urological evaluation matters because some therapies are most effective in specific disease phases.
Often saidVitamin E or oral supplements cure the curvature
ActuallyOral agents such as vitamin E and potassium para-aminobenzoate have not shown reliable efficacy for curvature in controlled data, and AUA does not recommend them for that purpose.
Often saidSurgery always lengthens the penis
ActuallyPlication, the most common straightening surgery, shortens the longer side and can reduce length. Patients are counseled on this trade-off before surgery.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Peyronie's disease is named for Francois Gigot de la Peyronie, surgeon to King Louis XV of France, who described the condition in 1743. For centuries treatment was limited to oral remedies and surgery of variable success. Intralesional therapies (verapamil, interferon) were explored through the late twentieth century with modest evidence. The field changed in 2013 when collagenase Clostridium histolyticum (already used for Dupuytren contracture, a related fibrotic disorder of the hand) became the first FDA-approved drug specifically for Peyronie's disease following the IMPRESS trials.
At a glance
- Lesion site
- Plaque in the tunica albuginea
- Phases
- Active (inflammatory/painful) then stable
- FDA-approved drug
- Collagenase Clostridium histolyticum (Xiaflex), 2013
- Xiaflex candidate
- Stable disease, curvature ~30-90 degrees, intact erections
- Definitive option
- Surgical plication, incision/grafting, or prosthesis
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Peyronie's Disease Treatment. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
IMPRESS I and II (pivotal phase 3 trials of collagenase, Gelbard et al.)2013
Intralesional collagenase plus modeling produced statistically significant improvement in penile curvature and Peyronie's bother score versus placebo, establishing the FDA-approved protocol of up to eight injections over the treatment course.
AUA Peyronie's Disease Guideline2015
Codified phase-based management: collagenase plus modeling for appropriate stable disease, surgery for stable/severe/calcified disease, and counseling on adverse events including corporal rupture.